Ads
related to: hyperphosphatemia treatment guidelines- About This Treatment
Learn More About This
Treatment Option
- Dosing Information
View Dosing & Prescribing
Information For This Treatment
- Copay Information
Learn More About Our
Copay Savings Program
- Safety Information
Important Safety Information
And Possible Side Effects
- About This Treatment
Search results
Results From The WOW.Com Content Network
Hyperphosphatemia is an electrolyte disorder in which there is an elevated level of phosphate in the blood. [1] Most people have no symptoms while others develop calcium deposits in the soft tissue. [1] The disorder is often accompanied by low calcium blood levels, which can result in muscle spasms. [1]
When kidney function is impaired, phosphate excretion declines. Without specific treatment, hyperphosphataemia occurs almost universally, despite dietary phosphate restriction and conventional dialysis treatment. [12] [13] In patients on dialysis, hyperphosphataemia is an independent risk factor for fractures, cardiovascular disease and mortality.
Treatment efforts may involve many clinical and diagnostic manoeuvers, such as trying to decrease phosphate, [7] normalize vitamin D (calcidiol levels) or decrease PTH and/or alkaline phosphatase levels. [8] However, there is an important lack of randomized clinical studies and recent guidelines (KDIGO 2017) have been recently released on the ...
There have been limited trials comparing phosphate binders to placebo in the treatment of hyperphosphatemia in people with chronic kidney disease. When compared with people receiving calcium-based binders, people taking sevelamer have a reduced all-cause mortality. [4]
Hyperphosphatemia causes acute kidney injury in tumor lysis syndrome, because of deposition of calcium phosphate crystals in the kidney parenchyma. [2] Hypocalcemia. Because of the hyperphosphatemia, calcium is precipitated to form calcium phosphate, leading to hypocalcemia. [2] Symptoms of hypocalcemia include (but are not limited to): [9] tetany
Sevelamer is a phosphate binding medication used to treat hyperphosphatemia in patients with chronic kidney disease. When taken with meals, it binds to dietary phosphate and prevents its absorption. Sevelamer was invented and developed by GelTex Pharmaceuticals.
Calcium acetate/magnesium carbonate is a fixed-dose combination drug that contains 110 mg calcium and 60 mg magnesium ions and is indicated as a phosphate binder for dialysis patients with hyperphosphataemia (abnormal high serum phosphorus levels). [1]
Nephrocalcinosis is connected with conditions that cause hypercalcaemia, hyperphosphatemia, and the increased excretion of calcium, phosphate, and/or oxalate in the urine. A high urine pH can lead to nephrocalcinosis but only if it is accompanied by hypercalciuria and hypocitraturia , since having a normal urinary citrate usually inhibits the ...
Ad
related to: hyperphosphatemia treatment guidelines